MedTrace Logo

Cross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation

NCT07771699 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-18

No results posted yet for this study

Summary

The goal of this clinical trial is to use different tES techniques to constantly stimulate the cerebellum in older glaucoma patients. The main questions aim to answer :

1. If the different types of tES targeting the cerebellum can modulate glaucoma patients' balance function and visual-cognitive function?
2. Which tES techniques among the two types can benefit most?

Participants will be required to receive the stimulation 15 times (3 sessions, 5 continuous days/session, 1-week interval between each session), and complete the balance and visual-cognitive function outcome measurements before and after each session.

Conditions

Interventions

OTHER

transcranial electrial stimulation

This intervention is uniquely designed to enhance balance function in patients with glaucoma using non-invasive cerebellar Transcranial Electrical Stimulation (tES), encompassing both transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Glaucoma-induced visual field loss disrupts the visual feedback critical for postural control, forcing patients to rely heavily on sensory re-weighting (integrating vestibular and proprioceptive inputs). The cerebellum is the central hub for this multi-sensory integration and motor adaptation. By modulating cerebellar excitability and neural oscillations, this intervention aims to facilitate sensory re-weighting, optimize vestibular-ocular/spinal reflexes, and ultimately improve dynamic and static balance.

Sponsors & Collaborators

  • The Hong Kong Polytechnic University

    lead OTHER

Principal Investigators

  • Allen Ming yan Cheong, PhD · The Hong Kong Polytechnic University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2029-11-01
Completion
2029-11-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07771699 on ClinicalTrials.gov